Mr Daniel Cohen
Consultant Urological Surgeon
Men's Health
Sub-specialties: General Urology, Prostate, Urological Cancer, Male LUTS, Benign Prostatic Hyperplasia (BPH), Prostate Cancer Diagnostics, Non-muscle Invasive Bladder cancer.
02036532042
Overview
Mr Daniel Cohen is a Consultant Urological Surgeon who diagnoses and treats prostate and bladder problems, with particular expertise in HoLEP and Aquablation surgery, investigation of raised PSA and blood in urine.
About Mr Daniel Cohen
Daniel Cohen is a Consultant Urological Surgeon. He completed a PhD in the Division of Surgery at Imperial College London and undertook surgical training in London, followed by a fellowship in laser prostate surgery (HoLEP). He is one of a few Consultants in North London to offer both HoLEP and Aquablation waterjet therapy for benign prostate enlargement and use of MRI-fusion biopsies to accurately diagnose prostate cancer.
Mr Cohen’s main clinical interests are in the diagnosis and management of prostate and bladder cancers, benign prostate enlargement and bladder function, in addition to a general urology practice covering peno-scrotal and testicular problems and urological emergencies.
Mr Cohen has sat on the European Association of Urology Bladder Cancer guidelines panel, acted as an advisor to Prostate Cancer UK and is a medical advisor to a national genetics charity and local cancer charities.
Areas of Expertise
Mr Daniel Cohen commonly treats:
- Elevated PSA
- Prostate cancer diagnostics
- Male urinary symptoms
- Prostate Enlargement
- Blood in Urine
He offers the following tests and treatments:
- HoLEP
- Aquablation
- MRI-US fusion Prostate Biopsy
Additional Information
Mr Daniel Cohen holds the following qualifications: PhD FRCS (Urol)
He is an active member of:
- European Association of Urology
- British Association of Urological Surgeons
He currently holds clinical posts at:
- Welbeck London
- Royal Free London NHS Foundation Trust (NHS and Private)
- Spire Bushey
- Centennial Medical Care
Research Highlights
Key publications:
Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk Non-muscle-invasive Bladder Cancer.
Contieri R, Martini A, Beijert IJ, Mertens LS, Hentschel AE, Bründl J, Compérat EM, Plass K, Rodríguez O, Subiela Henríquez JD, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Maxim Bruins H, Runneboom W, Herdegen S, Breyer J, Brisuda A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Seisen T, Claps F, Masson-Lecomte A, Liedberg F, Cohen D, Lunelli L, Cussenot O, Sheikh SE, Volanis D, Côté JF, Rouprêt M, Haitel A, Shariat SF, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, de Kaa CAH, van der Heijden AG, Kiemeney LALM, Soukup V, Molinaro L, Hurle R, Paciotti M, Moschini M, Pradere B, Perdonà S, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Ribal MJ, van der Kwast TH, Babjuk M, Sylvester RJ, van Rhijn BWG.
Eur Urol Oncol. 2025 Aug;8(4):977-985. doi: 10.1016/j.euo.2025.04.010. Epub 2025 May 21. PMID: 40399193European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Seisen T, Soukup V, Sylvester RJ.
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10. PMID: 34511303 (Review)European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, Bründl J, van der Kwast TH, Brisuda A, Rubio-Briones J, Seles M, Hentschel AE, Kusuma VRM, Huebner N, Cotte J, Mertens LS, Volanis D, Cussenot O, Subiela Henríquez JD, de la Peña E, Pisano F, Pešl M, van der Heijden AG, Herdegen S, Zlotta AR, Hacek J, Calatrava A, Mannweiler S, Bosschieter J, Ashabere D, Haitel A, Côté JF, El Sheikh S, Lunelli L, Algaba F, Alemany I, Soria F, Runneboom W, Breyer J, Nieuwenhuijzen JA, Llorente C, Molinaro L, Hulsbergen-van de Kaa CA, Evert M, Kiemeney LALM, N'Dow J, Plass K, Čapoun O, Soukup V, Dominguez-Escrig JL, Cohen D, Palou J, Gontero P, Burger M, Zigeuner R, Mostafid AH, Shariat SF, Rouprêt M, Compérat EM, Babjuk M, van Rhijn BWG.
Eur Urol. 2021 Apr;79(4):480-488. doi: 10.1016/j.eururo.2020.12.033. Epub 2021 Jan 6. PMID: 33419683Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria.
Tan WS, Ahmad A, Zhou Y, Nathan A, Ogunbo A, Gbolahan O, Kallam N, Smith R, Khalifeh M, Tan WP, Cohen D, Volanis D, Walter FM, Sasieni P, Kamat AM, Kelly JD.
Eur Urol Oncol. 2025 Feb;8(1):87-93. doi: 10.1016/j.euo.2024.05.005. Epub 2024 May 28.
Reviews
Major insurers served
If your insurer is not listed, please contact us to confirm your coverage. Please note this does not guarantee coverage or fee assurance. Patients should confirm with their insurer to ensure coverage, check if the doctor is fee-assured, or verify if their policy includes the doctor in question.
